

Trustworthy Deep Neural Network for Inferring Anticancer Synergistic Combinations

Muhammad A. Alsherbiny^{1,2,*}, Ibrahim Radwan³, Nour Moustafa⁴, Deep J. Bhuyan¹, Muath El-Waisi⁵,
Dennis Chang¹, Chun Guang Li^{1*}

Supplementary file

Content

Figure S1 Cell lines and combination count used for training per cancer type in different datasets.

Figure S2 Boxplot frequency distribution of Combination sensitivity and different synergy scores in (A) the processed DrugComb v1.3 dataset and its ALMANAC (B) and ONEIL(C) subsets.

Table S1 Common models of synergy quantitation.

Table S3 Synpredict MSE change % compared with other SynPredict variants or state of art regression models.




Figure S1 Cell lines and combination count used for training per cancer type in different datasets. A) Allocation of the total 76 cell lines used in SynPredict variants per various cancer types, B) and C) representing the counts of studied anticancer combinations per organ in ONEIL and ALMANAC datasets, respectively. H&L; Haematopoietic and lymphoid cancers.




Figure S2 Boxplot frequency distribution of Combination sensitivity and different synergy scores in (A) the processed DrugComb v1.3 dataset and its ALMANAC (B) and ONEIL(C) subsets.

Table S1 Common models of synergy quantitation.

Models	Theory and/or assumption	Limitation	Equation	software	Ref.
Loewe additivity	The sham mixture, no interaction expected of the drug with itself, and assume drugs have a constant potency ratio	Constant Potency ratio and parallel dose-response curves are rare	(1)	SynergyFinder, Chalice, CombiTool, Combenefit, GeneData DrugComb	¹
Bliss independence	Non-interaction , combination effect is due to 2 drugs don't interfere with each other and different site of action	Drug interactions in some drugs can't be excluded	(2)		²
Highest single agent (HSA) = Gaddum's pharmacological independence	The combination effect is superior to that achieved by single individual components	Any extra effect over the higher single drug will be considered as synergy Drug added to itself can produce an excess over HAS Too optimistic as the lowest threshold for synergy is considered	(3)		³
Zero interaction potency (ZIP),	-The combined effect is observed when the dose-response curve remains unchanged upon addition of the second drug -Hybrid model based on both Loewe additivity and Bliss independence	Dependence of accurate fitting of the dose-response curve to log-logistic curve which may be challenging for complex and low-quality dose-response data	(4)	DrugComb SynergyFinder	⁴
Median effect (Chou-Talalay)	Theorised based on median-effect equation and mass action law, and assume drugs have a constant potency ratio	Difficulty in the correct calculation of median effect doses due to nonlinearity and sigmoidicity of the dose-response curves	(5)	CompuSyn, Calcsyn, GeneData, PharmacGx	⁵

(1) $E_{AB} = E_A(a + a_b) = E_B(b_a + b)$ & $CI = a/A + b/B + c/C \dots n/N$

(2) $E_A + E_B(1 - E_A) = E_A + E_B - E_A E_B$ & $CI = (E_A + E_B - E_A \times E_B) / E_{AB}$

(3) $E_{AB} = \max(E_A, E_B)$ & $CI = \max(E_A, E_B) / E_{AB}$

$$E_{AB} = \frac{\left(\frac{[A]}{EC_{50,A}}\right)^{\lambda_A}}{1 + \left(\frac{[A]}{EC_{50,A}}\right)^{\lambda_A}} + \frac{\left(\frac{[B]}{EC_{50,B}}\right)^{\lambda_B}}{1 + \left(\frac{[B]}{EC_{50,B}}\right)^{\lambda_B}} - \frac{\left(\frac{[A]}{EC_{50,A}}\right)^{\lambda_A}}{1 + \left(\frac{[A]}{EC_{50,A}}\right)^{\lambda_A}} \frac{\left(\frac{[B]}{EC_{50,B}}\right)^{\lambda_B}}{1 + \left(\frac{[B]}{EC_{50,B}}\right)^{\lambda_B}}$$

(4)

(5) $f_a/f_u = (D/D_m)^{m^*}$ and $CI = D_1/E_1 + D_2/E_2$

$a + ab$; dose a giving the effect E_{AB} , $ba + b$; dose b giving the effect E_{AB} , CI ; combination index ($CI > 1$ antagonism; $CI = 1$ additivity; $CI < 1$ synergy), D ; a dose of the drug given, D_m ; median-effect dose, D_1 and D_2 ; actual drug doses used, E_1 and E_2 ; the theoretical individual drug levels that would be expected to be needed to achieve the experimentally measured response, E_A ; effect of drug A, E_B ; effect of drug B, E_{AB} ; effect of the combination of drug A and drug B, E_1 and E_2 ; theoretically individual drug levels expected to be required to produce the experimentally measured effect, $EC_{50,A}$ and $EC_{50,B}$; the half-maximal response of drug A and drug B, f_a ; the fraction of cells killed, f_u ; the fraction of living cells, m ; sigmoidicity of the dose-effect curve, R ; potency ratio $= A/B$, 'Sham mixture'; drug mixed with itself, λ_A and λ_B ; slope parameters of A and B dose response curves * ; median effect equation.

Table S2 Synpredict MSE change % compared with other SynPredict variants or state of art regression models.

A				
	SynPredict1	SynPredict2	SynPredict3	SynPredict4
TransSynergy-LOEWE	21.4	23.6	26.8	27
AuDNN-LOEWE	24.7	26.7	29.8	30
DeepSynergy-LOEWE	29	30.9	33.8	34
DrugComb-LOEWE	-100.13	-94.71	-86.44	-86
DrugComb-BLISS	3	67.3	-5.2	55.4
DrugComb-HSA	-1	72.2	10.6	73.5
DrugComb-ZIP	-0.79	45.24	-12.07	64.17
B				
	ONEIL to ALMANAC (IF)	ONEIL to ALMANAC (EF)	EF to IF (ONEIL)	EF to IF (ALMANAC)
LOEWE	2.715954	0.266115	-7.34477	-4.70798
BLISS	66.29075	57.64859	7.843456	26.64877
HSA	65.79028	63.21839	-11.58	-3.77799
S	63.66042	61.85795	-3.48035	1.409791
ZIP	45.6753	68.03245	10.06656	-52.8302
CSS	72.5846	70.80917	-124.529	-110.873

EF; early fusion, IF; intermediate fusion. The positive and negative values indicate enhancement and deterioration of the model performance, respectively. MSE change % = (MSE of the baseline- MSE of SynPredict variant)/MSE of the baseline x 100, where the state of art model's MSE or other SynPredict variant's MSE was considered as a baseline of comparison in A and B, respectively.

References

1. Loewe, S., The problem of synergism and antagonism of combined drugs. *Arzneimittelforschung* **1953**, 3, 285-290.
2. BLISS, C. I., THE TOXICITY OF POISONS APPLIED JOINTLY1. *Annals of Applied Biology* **1939**, 26 (3), 585-615.
3. Berenbaum, M. C., What is synergy? *Pharmacological Reviews* **1989**, 41 (2), 93-141.
4. Yadav, B.; Wennerberg, K.; Aittokallio, T.; Tang, J., Searching for Drug Synergy in Complex Dose–Response Landscapes Using an Interaction Potency Model. *Computational and Structural Biotechnology Journal* **2015**, 13, 504-513.
5. Chou, T.-C., Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies. *Pharmacological Reviews* **2006**, 58 (3), 621-681.



Muhammad A Alsherbiny received his master's in the chemistry of natural products from the faculty of Pharmacy, Cairo University, and currently, he is pursuing his PhD degree at NICM Health Research Institute, Western Sydney University, Australia. Multidisciplinary research areas such as proteomics, metabolomics, natural products, pharmacology, chemo/bioinformatics, cancer research and artificial intelligence applications in biomedicine are implemented in his current project mining for both effective and synergistic anticancer combinations.



Ibrahim Radwan received Ph.D. degree in computer science from the University of Canberra in 2015. From 2014 to 2016, he was a researcher in a leading automotive industry warehouse, a Research Fellow with The Australian National University and currently an assistant professor at the University of Canberra. His research includes developing and implementing algorithms in computer vision, machine learning, robotics, and artificial intelligence.



Nour Moustafa is the leader of Intelligent Security at SEIT, University of New South Wales, Canberra Australia. He received his PhD degree in the field of Cyber Security from UNSW Canberra in 2017. His areas of interest include Cyber Security, Network Security, IoT security, and machine learning techniques. He has several research grants totalling over 1.5 million. He was awarded the 2020 prestigious Australian Spitfire Memorial Defence Fellowship award. He is also

a Senior IEEE Member, ACM Distinguished Speaker, as well as CSCRC and Spitfire Fellow. He has served his academic community, as the guest associate editor of IEEE transactions journals, including IEEE Transactions on Industrial Informatics, IEEE IoT Journal, and IEEE Access. He has also served over seven conferences in leadership roles, involving vice-chair, session chair, Technical Program Committee (TPC) member and proceedings chair, including 2020-21 IEEE TrustCom and 2020 33rd Australasian Joint Conference on Artificial Intelligence.



Deep Buhyan Dr Buhyan received his PhD in pancreatic cancer therapeutics from The University of Newcastle, Australia in 2018 and has been working at NICM Health Research Institute, Western Sydney University as a Postdoctoral Research Fellow since then. His research centres on the development of novel antimicrobial and anticancer agents from natural sources and deciphering their molecular mechanisms of action. His current research is aimed at understanding the complex synergistic interactions among various phytochemicals and standard drugs on specific biological targets and how this can be utilised as therapeutic strategies against infectious/metabolic diseases and cancer. He has a strong research background investigating the anticancer and antimicrobial properties of plant extracts and bioactive compounds.



Dennis Chang Professor Dennis Chang is the Acting Director of NICM Health Research Institute. He is also a Professor of Pharmacology and the lead of NICM Health Research Institute's Healthy Hearts Research Program. Professor Chang's research interests include clinical and pharmacological studies of herbal medicine and other complementary medicine interventions at the Institute. He has led several significant clinical trials to evaluate the effect of herbal, yoga and tai chi for the treatment of dementia, mild cognitive impairment, coronary heart disease, metabolic syndrome and type 2 diabetes. Professor Chang has also led multiple laboratory-based pharmacological studies to evaluate pharmacokinetic/ bioavailability profiles and mechanisms of action underlying the neuro- and cardiac-protective effects of these medicines using a range of in vitro and in vivo models. His research has attracted significant research funding support from various external funding agencies, governments and industry totalling over \$6 million. Prior to his appointment in 2020 as the Institute's Acting Director, Professor Chang was the Institute's Associate Director International, Professor Chang.



Chun Guang Li. Professor Li commenced his current full-time role as Pharmacology leader at NICM in late 2012. In the previous five years he worked as a full time academic in the School of Health Sciences at RMIT University where he held the position of Director of the Chinese Medicine Research Group from 2007-2009 and was the leader of the Herbal Pharmacology and Toxicology group from 2008-2012. Li has directed a number of funded research projects and established an international reputation in the fields of pharmacology of complementary medicine in cancer and inflammation research. He conceptualised and managed various collaborative research projects with national and international institutions, and pharmaceutical industries. His main research interests include pharmacology of natural products, drug discovery, and traditional medicines.